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dialogue between health care authorities and the pharmaceutical industry to create 
true risk-sharing agreements.
PHP271
Risk-sHaRing scHemes in Poland - analysis and classification of Rss 
PRoPosed in ReimbuRsement aPPlication Received by aHtaPol in 2013
Iwanczuk T.1, Zawodnik S.1, Hermanowski T.R.2, Matusewicz W.1
1Agency for Health Technology Assessment in Poland (AOTM), Warsaw, Poland, 2Medical 
University of Warsaw, Warsaw, Poland
Objectives: To analyze and classify the Risk-Sharing Schemes (RSSs) proposed in 
reimbursement applications received by Agency for Health Technology Assessment 
in Poland (AHTAPol) in 2013. MethOds: Risk-Sharing Schemes proposed in reim-
bursement applications received by AHTAPol in 2013 were quantitatively and 
qualitatively analyzed. The classification of the RSSs was conducted based on both 
Carlson’s approach and the Polish Act on the reimbursement of medicinal prod-
ucts. Results: In the studied period, 80 reimbursement applications for medicines, 
special purpose dietary supplements or medical devices were received by AHTAPol. 
Among them, there were 52 RSSs for 51, medical technologies. They were classified 
into 5 categories according to the Act on the reimbursement. The most common 
category was making the official sales price dependent on a pay-back of a part 
of the reimbursement obtained to the entity which is obliged to finance benefits 
with public funds (48.08%). Further categories were: making the official sales price 
dependent on the applicant providing supplies at a reduced price as specified in the 
negotiations on the price of the medicine (15.38%), making the official sales price 
dependent on the level of turnover of the medicine (11.54%) and making the level 
of the applicant’s revenues dependent on the health effects achieved (1.92%). Other, 
nonclassified RSSs constituted 23.08% of all. Among 52 proposed RSSs only 17 of 
them could be classified according to the Carlson’s approach. As a results, 10 Price 
Volume Agreements, 6 Manufacturer funded treatment initiation and 1 Conditional 
treatment continuation were identified. cOnclusiOns: Most of the propositions 
are not considered to be RSS according to the Carlson’s approach. The most common 
propositions were related to pay-back of a part of the reimbursement obtained for 
each reimbursed package and did not included any risk sharing. There is a strong 
need for further research.
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For several years, there has been much discussion about the central role the National 
Institute for Health and Care Excellence (NICE) would play in the move to value-
based pricing (VBP) of drugs in England and Wales as part of the new Pharmaceutical 
Price Regulation Scheme (PPRS) scheduled to start in 2014. To date, there is no VBP 
model, but NICE and the PPRS have been disentangled, and NICE is currently con-
sulting on a proposal to include new terms of reference for value based assessment 
(VBA) in its Technology Appraisal Methods Guide. This would change the way in 
which it makes recommendations to the NHS and could become policy within a 
short time frame. Therefore, manufacturers need to be aware the implication of the 
VBA proposal on data requirements for NICE submissions. Currently, NICE reim-
bursement decisions are based on an incremental cost-effectiveness ratio threshold 
of £20,000/QALY, with factors such as innovation and National Health Service objec-
tives acting to increase the acceptable threshold up to £30,000/QALY, and end-of-life 
benefits potentially increasing the acceptable threshold further to £50,000/QALY. 
A key feature of the proposed VBA is the use of modifiers to numerically adjust 
the ICER (up to a maximum of 2.5 times the base ICER of £20,000/QALY, i.e £50,000/
QALY). The burden of the illness for which the drug is approved as well as its societal 
impact are two such modifiers. Precise guidance on applying burden of illness and 
societal impact modifiers to ICERs is currently lacking, although information may 
become available during summer 2014. However, there is some draft information 
on quantifying these modifiers. We will review all available information, including 
any post-consultation guidance, to provide an overview of data requirements and 
possible changes to cost-effectiveness models that manufacturers may need to 
consider for future VBAs.
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Objectives: A National immunization Technical Advisory Groups (NITAG) is a body 
of national experts that empowers and provides guidance to national health policy 
makers to enable them to make evidence-based decisions on immunisation. The 
aim of this study was 1) To develop a framework for the assessment of NITAGs that 
will allow to understand how closely their operations are aligned with best practice; 
2) to investigate whether differences with best practice are influenced by economic 
or geographic differences between countries; and 3) to understand the impact of 
NITAG alignment on the adoption of vaccines in the country’s national immunisation 
programme. MethOds: Building on previous initiatives mostly undertaken by the 
World Health Organization, we conducted interviews and in-depth research on 35 
NITAGs worldwide and built an assessment framework with 48 indicators to evaluate 
NITAG Alignment with international guidance. Results: The assessment revealed 
that there is a high variability in the degree of NITAG Alignment between countries 
which could not be explained by differences in GDP per capita, health expenditure 
per capita, or geographic location. Countries with a reasonably well-aligned NITAG 
have a higher proportion of the WHO-recommended and additional vaccines in their 
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Objectives: A growing number of health technologies are coming to market 
with limited, yet promising, clinical data. Coverage with evidence development 
(CED), a conditional interim reimbursement scheme linked to research to reduce 
uncertainty, has been increasingly explored by payers worldwide. The objective 
was to summarize CED programs worldwide, and report final reimbursement deci-
sions. MethOds: A search was conducted using published literature, websites and 
grey literature to identify CED programs worldwide from 1998 to 2012. Results: 
Seventy-four CED schemes were identified in Canada (n= 23), Sweden (n= 16), United 
States (n= 14), UK (n= 11), Australia (n= 4) and Europe (n= 6). CED schemes were found 
in oncology (n= 21), heart disease (n= 12), diabetes (n= 10), Neurological disorders 
(n= 7), multiple sclerosis (n= 2), mental health (N= 3), rheumatoid arthritis (N= 1), 
and other (N= 18). Drugs, imaging techniques, surgical procedures, and devices 
were most commonly evaluated. Most CED programs aimed to address more than 
one type of uncertainty. The most commonly encountered uncertainty was clini-
cal benefit, followed by value for money, adoption and diffusion, and affordability. 
Study designs included interventional, clinical, observational, and economic studies. 
CED programs were generally managed by independent, government-funded non-
profit research organizations, university-based academic centers, or professional 
societies. In only 39% (N= 28) of the identified CED schemes, study outcomes and 
funding decisions were reported. In 74% (N= 17) of reported cases, the technology 
evaluated was successfully funded. One technology (lung volume reduction surgery) 
was only funded in a subgroup, and one technology was funded with price reduc-
tion. On many accounts CED has proven challenging to implement. cOnclusiOns: 
Although a large number of CED activities were identified, detailed information, 
especially the study outcomes and final reimbursement decision, only limited infor-
mation of final decisions was publically available. CED is a promising mechanism to 
reduce uncertainty and aid timely patient access, but with emerging implementa-
tion challenges.
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Objectives: To compare Managed Entry Agreements (MEAs) in the UK, Italy, and 
Spain, and analyse the type of MEAs, number of agreements, and therapy areas in 
which they exist. Finally, to determine MEA impact on market access delay in these 
countries. MethOds: HTA databases were searched for types and quantities of 
MEAs (publicly available). The data were analysed by indication, and country spe-
cific knowledge applied, to quantify the average delay to market access. Results: 
All types of MEA have been granted previously in the UK, the majority were non-
outcomes based (76%). In Italy, and Spain, all MEA’s were outcomes based, with 
Italy focused purely on risk-sharing agreements. UK has 42 MEA’s since 2000, Italy 
has 44 MEAs since 2006 and Spain has 9 MEAs since 2010. Of 95 MEAs, 56% were for 
oncology drugs, 12% musculoskeletal, 10% ophthalmology, 7% CNS, 5% respiratory 
and 10% other therapy areas. NICE average time to HTA decision is 21 months, and 
is delayed up to 10 months depending on the type of MEA. AIFA average time to HTA 
decision is 8 months; however MEAs are part of the pricing negotiation, so it may 
be a way to gain market access faster. In Spain, the average time to HTA decision 
is 8 months with decisions for drugs with double pricing arrangements taking on 
average 14 months. For high cost hospital and orphan drugs, the delay can be up to 
a year. cOnclusiOns: Negative reimbursement decisions can have a significant 
impact on achieving market access, and revenue generation. MEAs represent an 
avenue for overcoming these negative decisions and market access for high cost 
medicines. Companies aiming for MEAs in UK, Italy, and Spain, should be aware of 
the potential market access delay and the precedence of MEAs that the payers in 
these countries are amenable to.
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Objectives: The aim of this project was to evaluate risk-sharing agreements that 
are currently being negotiated in Europe between health care authorities and the 
pharmaceutical industry. MethOds: A literature review of the grey literature 
(reports of the Organization for Economic Co-operation and Development and WHO 
Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies) as 
well as peer-reviewed literature (PUBMED) was done to explore the background of 
this topic. Semi-structured interviews were conducted with representatives of the 
pharmaceutical industry, consultant agencies and health care authorities to get 
their opinions about the current state of risk-sharing agreements. Results: The 
study identified multiple problems in risk-sharing agreements such as insufficient 
terminology and methodology, the absence of adequate infrastructure for imple-
mentation and a lack of trust and dialogue between the establishing parties: health 
care authorities and pharmaceutical industry. These issues question the crucial con-
cept of sharing the risks equally and disgrace the agreements, even though it would 
be of great value to overcome current challenges. Such agreements could help the 
health care authorities to keep within their budget while still providing innovative 
pharmaceutical products/treatments to the patients. In addition, the pharmaceuti-
cal industry would have the opportunity to bring its products to the market and 
patients would benefit from adequate pricing and reimbursement. cOnclusiOns: 
In spite of the current problems, the popularity of risk-sharing agreements in Europe 
is growing fast and the future is bright. For this reason there is a strong need for 
